UBS Group
KYNB

UBS Group’s Kyntra Bio KYNB Stock Holding History

UBS Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,000
Closed -$88.6K – 9521
2023
Q4 		$88.6K Hold
4,000
– – ﹤0.01% 6238
2023
Q3 		$86.3K Buy
+4,000
New +$157K ﹤0.01% 5930

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

UBS Group's KYNB Position: Q2 2026 in Review

UBS Group reduced its Kyntra Bio (KYNB) stake by 72% in Q2 2026, selling an estimated $138K and leaving 7,857 shares worth $59.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7475.

UBS Group first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.9M in Q1 2018. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • UBS Group held 7,857 shares of Kyntra Bio worth $59.3K as of Q2 2026.
  • UBS Group sold 19,734 Kyntra Bio shares in Q2 2026, an estimated $138K.
  • Kyntra Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7475 holding.
  • UBS Group first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Kyntra Bio position peaked at $7.9M in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.